Metalloproteinase-9 gene variants and risk for hypertension among ethnic Javanese

Main Article Content

Fitranto Arjadi
Saefuddin Aziz
Alfi Muntafiah

Abstract

Background
Hypertension is associated with endothelial-dependent vasodilation disorders, due to reduced nitric oxide (NO) availability and excessive angiotensin II (ANG-II) activation. The objective of this study was to determine the association between matrix metallopeptidase 9 (MMP-9) gene polymorphism and hypertension in ethnic Javanese in the 40-80 year age group.

Methods
This was a case-control study on 50 PROLANIS patients of family doctors meeting the inclusion criteria and 50 controls without hypertension. Subjects were hypertensive patients with constant systolic arterial pressure of >140 mmHg and diastolic arterial pressure of >90 mmHg, confirmed in three successive measurements The observed parameters were degree of MMP-9 polymorphism, and NO and ANG-II levels. Matrix metallopeptidase 9 polymorphism was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) using the SmaI restriction enzyme. MMP-9 polymorphisms were indicated by variation in band patterns. Degree of polymorphism in cases and controls were compared with NO and ANG-II levels in both groups. Data analysis was done using independent t-test.

Results
The heterozygous (3 band) to normal (2 band) MMP-9 genotype ratio was 3:1 in hypertensives, but balanced in controls. In hypertensives, heterozygous GA and homozygous AA genotype frequencies were respectively 3.198 and 1.548 times higher than that of the GG genotype (p=0.008 and p=0.726). There was a statistically significant differences of NO and Ang-II levels between cases and controls (p=0.000 and p=0.000; respectively).

Conclusion
Matrix metallopeptidase 9 gene polymorphisms in hypertensive ethnic Javanese are associated with NO and angiotensin II levels.

Article Details

How to Cite
Arjadi, F., Aziz, S., & Muntafiah, A. (2014). Metalloproteinase-9 gene variants and risk for hypertension among ethnic Javanese. Universa Medicina, 33(3), 213–220. https://doi.org/10.18051/UnivMed.2014.v33.213-220
Section
Review Article

References

Sugiharto A. Faktor-faktor risiko hipertensi grade II pada masyarakat (studi kasus di Kabupaten Karanganyar) [Thesis]. Semarang: Universitas Diponegoro;2007.

Rahajeng E, Tuminah S. Prevalensi hipertensi dan determinannya di Indonesia. MKI 2009;15: 580-4.

Dinas Kesehatan Kota Banyumas. Kasus penyakit tidak menular di puskesmas dan rumah sakit Kabupaten Banyumas- profil puskesmas dan rumah sakit Kabupaten Banyumas 2008:88.

Karthikeyan VJ, Lip GYH. Matrix metalloproteinases and hypertension: a link between left ventricular hypertrophy and diastolic dysfunction. Tohoku J Exp Med 2006; 28:93-7.

Armstrong C, Abilleira S, Sitzer M, Markus HS, Bevan S. Polymorphisms in MMP family and TIMP genes and carotid artery intima-media thickness. Stroke 2007;38:2895-9.

Niu W, Qi Y. Matrix metalloproteinase family gene polymorphisms and risk for coronary artery disease: systematic review and meta-analysis. Heart 2012;98:1483-91.

Hingorani AD, Liang CF, Fatibene J, Lyon A, Monteith S, Parsons A, et al. A common variantof the endothelial nitric oxide synthase (Glu298—>Asp) is a major risk factor for coronary artery disease in the UK. Circ 1999; 100:1515-20.

Ye S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res 2006;69:636-45.

Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004;15:1983-92.

Zhou S, Feely J, Spiers J, Mahmud A. Matrix metalloproteinase-9 polymorphism contributes to blood pressure and arterial stiffness in essential hypertension. J Hum Hypertens 2007;21:861-7.

Mishra A, Srivastava A, Mittal T, Garg N, Mittal B. Association of matrix metalloproteinases (MMP2, MMP7 and MMP9) genetic variants with left ventricular dysfunction in coronary artery disease patients. Clinica Chimica Acta 2012;413:1668-74.

Mazzotti DR, Singulane CC, Ota VK, Rodrigues TP, Furuya TK, de Souza FJ, et al. Association of APOE, GCPII and MMP9 polymorphisms with common diseases and lipid levels in an older adult/elderly cohort. Gene 2014;535:370-5.

Yang J, Wu B, Lin S, Zhou J, Li Y, Dong W, et al. Genetic variations of MMP9 gene and intracerebral hemorrhage susceptibility: a case-control study in Chinese Han population. J Neurol Sci 2014;341:55-7.

Miller S, Dykes D, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.

Lacchini RJF, Luizon MR, Coeli FB, Izidoro-Toledo TGS, Ferreira-Sae MC, Schreiber RN, et al. Matrix metalloproteinase 9 gene haplotypes affect left ventricular hypertrophy in hypertensive patients. Clinica Chimica Acta 2010;411:1940–4.

Fan ZZ1, Ge ZM, Cai HB, Liu ZY, Liu P, Wang HY. Association between the MMP-9-1562 C>T polymorphism and the risk of stroke: a meta-analysis. Mol Biol Rep 2014;41:6787-94. doi: 10.1007/s11033-014-3564-0.

Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002;90: 251-62.

Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 2005;97: 434-42.

Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circ 2003;107: 1579-85.

Alp E, Menevse S, Tulmac M, Kan D, Yalcin R, Erkan AF, et al. Lack of association between matrix metalloproteinase-9 and endothelial nitric oxide synthase gene polymorphisms and coronary artery disease in Turkish population. DNA Cell Biol 2009;28:343-50.

Ridnour LA, Windhausen AN, Isenberg JS, Yeung N, Thomas DD, Vitek MP, et al. Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and independent pathways. Proc Nat Acad Sci USA 2007;104:16898-903.

Knipp BS, Ailawadi G, Ford JW, Peterson DA, Eagleton MJ, Roelofs KJ, et al. Increased MMP-9 expression and activity by aortic smooth muscle cells after nitric oxide synthase inhibition is associated with increased nuclear factor-êB and activator protein-1 activity. J Surg Res 2004;116: 70-80.

Alp E, Menevse S, Tulmac M, Kan D, Yalcin R, Erkan AF, et al. Lack of association between matrix metalloproteinase-9 and endothelial nitric oxide synthase gene polymorphisms and coronary artery disease in Turkish population. DNA Cell Biol 2009;28:343-50.

Yaghooti H, Firoozrai M, Fallah S, Khorramizadeh M. Angiotensin II induces NF-êB, JNK and p38 MAPK activation in monocytic cells and increases matrix metalloproteinase-9 expression in a PKC-and Rho kinase-dependent manner. Braz J Med Biol Res 2011;44:193-9.

Knipp BS, Ailawadi G, Ford JW, Peterson DA, Eagleton MJ, Roelofs KJ, et al. Increased MMP-9 expression and activity by aortic smooth muscle cells after nitric oxide synthase inhibition is associated with increased nuclear factor-êB and activator protein-1 activity. J Surg Res 2004;116: 70-80.

Medley TL, Kingwell BA, Gatzka CD, Pillay P, Coleet TJ. Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res 2003;92:1254-1261.